A Prospective, Multicentre, Non-interventional, Observational, Cohort Study to Evaluate the Long Term Clinical, Patient Reported and Health Care Resource Utilization Effects of an Early Response to Certolizumab Pegol (Cimzia) in Rheumatoid Arthritis Patients in Daily Clinical Practice in the United Kingdom and Eire.

Trial Profile

A Prospective, Multicentre, Non-interventional, Observational, Cohort Study to Evaluate the Long Term Clinical, Patient Reported and Health Care Resource Utilization Effects of an Early Response to Certolizumab Pegol (Cimzia) in Rheumatoid Arthritis Patients in Daily Clinical Practice in the United Kingdom and Eire.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RA-PROACTIVE
  • Sponsors UCB
  • Most Recent Events

    • 30 Jun 2016 Time frame in primary endpoint has changed from Baseline (Week 0),18 moths to Baseline (Week 0), 78 weeks.
    • 27 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 23 Jul 2014 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top